Newsroom

Press Release

NeoGenomics Announces Public Offering of Common Stock

NeoGenomics Reports Record Revenues of $20.7 Million on 40% Test Volume Growth and Expanding Gross Margins for the Second Quarter 2014

NeoGenomics Expands Next Generation Sequencing Services and Offers 23 Different Profiles for Various Hematologic and Solid Cancers

NeoGenomics Completes Acquisition of Path Logic

NeoGenomics Raises Guidance and Projects 30% Year-Over-Year Revenue Growth in Quarter 2, 2014

NeoGenomics Schedules its Q2 2014 Earnings Release for July 17, 2014

NeoGenomics Selected by Aurora Diagnostics as Primary Partner for Molecular, FISH, and Immunohistochemistry Testing

NeoGenomics Reports Revenue of $18.2 Million and Adjusted EBITDA of $1.7 million for the First Quarter

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients